Author Interviews, Environmental Risks / 07.05.2024

MedicalResearch.com Interview with: [caption id="attachment_61654" align="alignleft" width="150"]Gediminas "Gedi" Mainelis, Ph.D.Professor, Department of Environmental Sciences School of Environmental and Biological Sciences Rutgers, The State University of New Jersey Prof. Mainelis[/caption] Gediminas "Gedi" Mainelis, Ph.D. Professor, Department of Environmental Sciences School of Environmental and Biological Sciences Rutgers, The State University of New Jersey MedicalResearch.com: What is the background for this study? What types of particles, ie where do they come from? Response: This work is a continuation of my research on nanoparticles in consumer products. We have investigated and published on the release of particles from nano-enabled consumer products, such as cosmetic powders, various sprays and clothing. In this project, we were interested in potential resuspension of particles once nano-enabled consumer sprays are used. The particles are added into consumer products to provide them certain desired properties, like antimicrobial protection, odor reduction or protection against UV (sunscreen). Once the products are used, the particles are released and we could be exposed to them.
Author Interviews, Cancer Research, JAMA / 06.09.2022

MedicalResearch.com Interview with: [caption id="attachment_59506" align="alignleft" width="130"]Samir Parekh, MBBS Hematology-Oncology, Cancer Director of Translational Research in Myeloma and Co-leader of the Cancer Clinical Investigation program The Tisch Cancer Institute Icahn School of Medicine at Mount Sinai Dr. Parekh[/caption] Samir Parekh, MBBS Hematology-Oncology, Cancer Director of Translational Research in Myeloma and Co-leader of the Cancer Clinical Investigation program The Tisch Cancer Institute Icahn School of Medicine at Mount Sinai MedicalResearch.com: What is the background for this study? What are the main findings? Response: Clinical outcomes for myeloma patients patients have improved significantly over the past decade with the introduction and success of newer immunomodulatory treatments such as CART cell therapy and bispecific antibodies. Strategies are needed to determine the best treatment options for patients relapsing or unresponsive to initial courses of these types of therapies. We analyzed the outcomes of patients relapsing after bispecific antibody therapy for myeloma. Our data shows that sequencing of bispecific antibodies or CART after initial bispecific failure can effectively salvage patients and lead to excellent outcomes in myeloma. This provides the foundation for future studies combining this new class of immunotherapy with CART or additional bispecific antibodies to improve outcomes in myeloma.
Author Interviews, Environmental Risks, Toxin Research / 01.05.2021

MedicalResearch.com Interview with: [caption id="attachment_57291" align="alignleft" width="118"]Hong-Sheng Wang PhD Department of Pharmacology and Systems Physiology University of Cincinnati College of Medicine, Cincinnati Dr. Hong-Sheng Wang[/caption] Hong-Sheng Wang PhD Department of Pharmacology and Systems Physiology University of Cincinnati College of Medicine, Cincinnati MedicalResearch.com: What is the background for this study? What is the significance of tritan? Response: Bisphenol A (BPA) is used widely in the manufacturing of consumer plastic goods. Researchers and the general public increasingly recognize the potentially harmful effect of BPA. These days BPA-based polycarbonate plastic water bottles have all but disappeared in most US stores, replaced by various BPA-free bottles including Tritan bottles. Tritan is a plastic that is not based on BPA or BPA analogues. In earlier studies, we unexpectedly found transient release of BPA from some Tritan bottles. Similar results have been reported in a past study. We wanted to figure out why the BPA release from Tritan bottles, and how consumers can best clean their bottles.
Author Interviews, Microbiome, Surgical Research, Weight Research / 11.01.2019

MedicalResearch.com Interview with: [caption id="attachment_46883" align="alignleft" width="147"]Casey Morrow, Ph.D. Leader of the research team and professor emeritus Department of Cell, Developmental and Integrative Biology University of Alabama at Birmingham Dr. Morrow[/caption] Casey Morrow, Ph.D. Leader of the research team and professor emeritus Department of Cell, Developmental and Integrative Biology University of Alabama at Birmingham MedicalResearch.com: What is the background for this study? Response: The human gastrointestinal tract (GIT) contains several distinct physical environments within the stomach, small intestine (duodenum, jejunum, ileum) and colon that harbor complex microbial communities. Changes in the fecal microbe composition have been described for Roux-en-Y gastric bypass (RYGB), the most effective and durable treatment for morbid obesity, and sleeve gastrectomy (SG).